These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 9893703

  • 1. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
    Lopaschuk GD.
    Presse Med; 1998 Dec 12; 27(39):2100-4. PubMed ID: 9893703
    [Abstract] [Full Text] [Related]

  • 2. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
    Lopaschuk GD.
    Am J Cardiol; 1998 Sep 03; 82(5A):14K-17K. PubMed ID: 9737481
    [Abstract] [Full Text] [Related]

  • 3. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
    Labrid C.
    Rom J Intern Med; 1998 Sep 03; 36(3-4):137-44. PubMed ID: 10822510
    [Abstract] [Full Text] [Related]

  • 4. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    Kantor PF, Lucien A, Kozak R, Lopaschuk GD.
    Circ Res; 2000 Mar 17; 86(5):580-8. PubMed ID: 10720420
    [Abstract] [Full Text] [Related]

  • 5. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD, Barr R, Thomas PD, Dyck JR.
    Circ Res; 2003 Aug 08; 93(3):e33-7. PubMed ID: 12869392
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
    Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, Quan N, Wang L, Yang H, Guo HM, Li J, Zhuang J, Zhu P.
    Metabolism; 2016 Mar 08; 65(3):122-30. PubMed ID: 26892523
    [Abstract] [Full Text] [Related]

  • 8. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC, Marzilli M.
    Fundam Clin Pharmacol; 2003 Apr 08; 17(2):133-45. PubMed ID: 12667223
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
    Mody FV, Singh BN, Mohiuddin IH, Coyle KB, Buxton DB, Hansen HW, Sumida R, Schelbert HR.
    Am J Cardiol; 1998 Sep 03; 82(5A):42K-49K. PubMed ID: 9737485
    [Abstract] [Full Text] [Related]

  • 11. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
    Stanley WC, Sabbah HN.
    Heart Fail Rev; 2005 Dec 03; 10(4):275-9. PubMed ID: 16583175
    [No Abstract] [Full Text] [Related]

  • 12. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH.
    Circ Res; 2003 Aug 08; 93(3):e26-32. PubMed ID: 12869391
    [Abstract] [Full Text] [Related]

  • 13. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
    Rosano GM, Vitale C, Fragasso G.
    Am J Cardiol; 2006 Sep 04; 98(5A):14J-18J. PubMed ID: 16931201
    [Abstract] [Full Text] [Related]

  • 14. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia.
    Monteiro P, Duarte AI, Gonçalves LM, Moreno A, Providência LA.
    Eur J Pharmacol; 2004 Oct 25; 503(1-3):123-8. PubMed ID: 15496306
    [Abstract] [Full Text] [Related]

  • 15. Metabolic management of ischemic heart disease: clinical data with trimetazidine.
    Desideri A, Celegon L.
    Am J Cardiol; 1998 Sep 03; 82(5A):50K-53K. PubMed ID: 9737486
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS, Hill JA.
    Am J Cardiovasc Drugs; 2001 Sep 03; 1(1):23-35. PubMed ID: 14728049
    [Abstract] [Full Text] [Related]

  • 20. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
    Wenmeng W, Qizhu T.
    Med Hypotheses; 2011 Feb 03; 76(2):181-3. PubMed ID: 20932648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.